Methods for stabilizing oxidatively unstable compositions

ABSTRACT

Ophthalmic compositions and methods of preparing such compositions are disclosed.

RELATED APPLICATION

This application claims priority from a non-provisional filing, U.S. App. Pat. No. 60/783,557 entitled “Methods for Stabilizing Oxidatively Unstable Pharmaceutical Compositions,” which was filed on, Mar. 17, 2006.

FIELD OF THE INVENTION

This invention related to compositions of oxidatively unstable ophthalmic ingredients and methods for preparing such compositions

BACKGROUND

Therapeutic agents for topical administration to the eye are generally formulated in either a liquid or gel form and must be kept sterile until administration. Accordingly, ophthalmic therapeutic agents are either packaged asceptically, which is cumbersome and expensive or are heat sterilized. Unfortunately, many therapeutic agents are not oxidatively stable, especially at elevated temperatures.

EDTA, Dequest, and Desferal have been used to improve the stability of certain therapeutic agents during autoclaving. However, there remains a need for other compounds capable of stabilizing unstable therapeutic agents that are susceptible to oxidative degradation. This need is met by the following invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 Stability Study with Ketotifen and PAA or EDTA

FIG. 2. Stability Study with Ketotifen and PAA or EDTA

FIG. 3 Stability Study with Ketotifen and PAA or DTPA

DETAILED DESCRIPTION OF THE INVENTION

This invention includes a method of stabilizing an ophthalmic composition comprising an oxidatively unstable pharmaceutical ingredient wherein said method comprises adding an effective amount of a stabilizing agent to the ophthalmic composition.

As used herein “oxidatively unstable pharmaceutical ingredient” refers to pharmaceutical or nutraceutical compounds used to treat conditions of the eye, and such compound degrade in the presence of oxygen and certain transition metals. Examples of pharmaceutical compounds include antihistamines, antibiotics, antibacterial agents, antiviral agents, antifungal agents, analgesics, anesthetics, antiallergenic agents, mast cell stabilizers, steroidal and non-steroidal anti-inflammatory agents, angiogenesis inhibitors; antimetabolites, fibrinolytics, neuroprotective drugs, angiostatic steroids, mydriatics, cyclopegic mydriatics; miotics; vasoconstrictors; vasodilators, anticlotting agents; anticancer agents, antisense agents, immunomodulatory agents, carbonic anhydrase inhibitors, integrin antabonistsl; cyclooxygenase inhibitors, VEGF antagonists; immunosuppressant agents and the like. Particularly, examples of pharmaceutical agents include but are not limited to acrivastine, antazoline, astemizole, azatadine, azelastine, buclizine, bupivacaine, cetirizine, clemastine, cyclizine, cyproheptadine, ebastine, emedastine, ephedrine, eucatropine, fexofenadine, homatropine, hydroxyzine, ketotifen, levocabastine, levoceterizine, lomefloxacin, meclizine, mepivacaine, mequitazine, methdilazine, methapyrilene, mianserin, naphazoline norastemizole, norebastine, ofloxacin, oxymetazoline, pheniramine, phenylephrine, physostigmine, picumast, promethazine, scopolamine, terfenadine, tetrahydozoline, thiethylperazine, timolol, trimeprazine, triprolidine, pharmaceutically acceptable salts and mixtures thereof. Preferred pharmaceutical compounds include acrivatine, antazoline, astemizole, azatadine, azelastine, clemastine, cyproheptadine, ebastine, emedastine, eucatropine, fexofenadine, homatropine, hydroxyzine, ketotife, levocabastine, levoceterizine, meclizine, mequitazine, methdialazine, methapyrilene, norastemizole, norebastine, oxymetazoline, physootigmine, picumast, promethazine, scopolamine, terfenadine, tetrahyerozoline, fimilol, trimeprazine, triprolidine, and pharmaceutically acceptable salts thereof. Particularly preferred pharmaceutical compounds include phenarimine, ketotifen, ketotifen fumarate nor ketotifen, olopatadine and mixtures thereof. More particularly preferred pharmaceutical compounds include ketotifen, its pharmaceutically acceptable salts, and mixtures thereof.

Examples of nutraceutical compounds include vitamins and supplements such as vitamins A, D, E, lutein, zeaxanthin, lipoic acid, flavonoids, ophthalmicially compatible fatty acids, such as omega 3 and omega 6 fatty acids, combinations thereof, combinations with pharmaceutical compounds and the like. Preferred pharmaceutical or nutraceutical compounds are those that degrade when solutions of these compounds and oxidative catalysts (such as metals and metallic salts) are mixed together at ambient or elevated temperatures, as compared to solutions of these compounds without oxidative catalysts at ambient or elevated temperatures. Particularly preferred pharmaceutical or nutraceutical compounds are those that degrade greater than about 10% when heated to about 120° C. for about 20 minutes with oxidative catalysts. The concentration of oxidatively unstable pharmaceutical ingredients in the ophthalmic compositions of the invention range from about 2 μg/mL to about 0.5 g/mL, particularly preferred, about 0.1 μg/mL to about 10,000 μg/mL.

The term “ophthalmic composition” refers to liquids, aerosols, or gels that may be topically administered to the eye. The term “stabilizing agent” refers to chelant compositions that inhibit metal catalyzed oxidative degradation of the oxidatively unstable pharmaceutical ingredient. Examples of stabilizing agents include but are not limited to silica, chitin derivative such as chitosan, polyamides such as poly(aspartic acid-co-w-amino acid (See CAN:129:54671, Shibata, Minako et al. Graduate School Environmental Earth Science, Hokkaido University, Sapporo, Japan Macromolecular Symposia (1998), 130, 229-244) and polymeric amides such as poly[iminocarbonyl(2,5-dihydroxy-1,4-phenylene)carbonylimino-1,4-phenylenemethylene-1,4-phenylene], CAS #87912-00-3, polymeric lactams such as polyvinylpyrrolidone, polyamino carboxylic acids such as diethylenetriaminepentaacetic acid and triethylenetriaminepentaacetic acid, polymeric amines such as polyallylamine, crown ethers such as 18-crown-6, 21-crown-7, and 24-crown-8, cellulose and its derivatives, and N,N,N′,N′,N″, N″-hexa(2-pyridyl)-1,3,5-tris(aminomethyl)benzene, and certain macrocyclic ligands such as crown ethers, ligand containing knots and catenands (See, David A. Leigh et al Angew. Chem Int. Ed., 2001, 40, No. 8, pgs. 1538-1542 and Jean-Claude Chambron et al. Pure & Appl. Chem., 1990, Vol. 62, No. 6, pgs. 1027-1034) The preferred stabilizing agents are polyamino carboxylic acids such as diethylenetriaminepentaacetic acid and triethylenetriaminepentaacetic acid. The particularly preferred stabilizing agents are diethylenetriaminepentaacetic acid (“DTPA”), or salts of DTPA such as CaNa₃DTPA, ZnNa₃DTPA, and Ca₂DTPA. The term “effective amount” refers to the amount of stabilizing agent required to inhibit the oxidative degradation of the pharmaceutical ingredient. In most circumstances it is preferred that there is a 1:1 molar ration of metal present in the ophthalmic composition to chelant, is more preferably about 1 of metal to greater than about 1 of chelant compositions, most preferably about 1 of metal to greater than or equal to about 2 of chelant compositions. With respect to concentration limits, it is preferred that the stabilizing agents have a concentration in the ophthalmic composition from about 2.5 μmoles/liter to about, 5000 μmoles/liter more preferably from about 20 μmoles/liter to about 1000 μmoles/liter, more preferably from about 100 μmoles/liter to about 1000 μmoles/liter, most preferably from about 100 μmoles/liter to about 500 μmoles/liter.

Aside from the oxidatively unstable pharmaceutical ingredient and the stabilizing agent, the ophthalmic composition contains suitable ophthalmic carriers. Suitable carriers include antioxidants (radical scavengers), demulcents, antibacterial agents, solubilizers, surfactants, buffer agents, tonicity adjusting agents, chelating agents, preservatives, wetting agents, thickeners, water, saline solution, mineral oil, petroleum jelly, water soluble solvents, such as C₁₅₋₂₀ alcohols, C₁₅₋₂₀ amides, C₁₅₋₂₀ alcohols substituted with zwitterions, vegetable oils or mineral oils comprising from 0.5 to 5% by weight hydroxyethylcellulose, ethyl oleate, carboxymethylcellulose, polyvinylpyrrolidone and other non-toxic water-soluble polymers for ophthalmic uses, such as, for example cellulose derivatives, such as methylcellulose, alkali metal salts of carboxy-methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropyl-cellulose, hydroxypropylcellulose, chitosan and scleroglucan, acrylates or methacrylates, such as salts of poly(acrylic acid) or ethyl acrylate, polyacrylamides, natural products, such as gelatin, alginates, pectins, tragacanth, karaya gum, xanthan gum, carrageenin, agar and acacia, starch derivatives, such as starch acetate and hydroxypropyl starch, and also other synthetic products, such as poloxamers, e.g. Poloxamer F127, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, polyethylene oxide, preferably cross-linked poly(acrylic acid), such as neutral Carbopol, or mixtures of those polymers. Preferred carriers are water, cellulose derivatives, such as methylcellulose, alkali metal salts of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropylcellulose and hydroxypropylcellulose, neutral Carbopol, or mixtures thereof. The concentration of the carrier is, for example, from 0.1 to 100000 times the concentration of the active ingredient combinations thereof and the like. When the ophthalmic composition is an eye drop, preferred carriers include water, pH buffered saline solution, mixtures thereof and the like. The preferred carrier is an aqueous saline solution containing salts including, without limitation, sodium chloride, sodium borate, sodium phosphate, sodium hydrogenphosphate, sodium dihydrogenphosphate, or the corresponding potassium salts of the same. These ingredients are generally combined to form buffered solutions that include an acid and its conjugate base, so that addition of acids and bases cause only a relatively small change in pH. The buffered solutions may additionally include 2-(N-morpholino)ethanesulfonic acid (MES), sodium hydroxide, 2,2-bis(hydroxymethyl)-2,2′,2″-nitrilotriethanol, n-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid, citric acid, sodium citrate, sodium carbonate, sodium bicarbonate, acetic acid, sodium acetate, ethylenediamine tetraacetic acid and the like and combinations thereof. Most preferably, the carrier is a borate buffered or phosphate buffered saline solution.

Further the invention includes an ophthalmic composition comprising an oxidatively unstable pharmaceutical ingredient and an effective amount of a stabilizing agent. The terms oxidatively unstable pharmaceutical ingredient, effective amount, and stabilizing agents all have their aforementioned meanings and preferred ranges.

Still further the invention includes a method of stabilizing an ophthalmic composition comprising an oxidatively unstable excipient wherein said method comprises adding an effective amount of a stabilizing agent to the ophthalmic composition.

As used herein “oxidatively unstable excipient” refers to a component of ophthalmic compositions that degrades in the presence of oxygen and certain transition metals. Examples of unstable excipients include but are not limited to astringents, demulcents, emollients, hypertonicity agents, oleaginous, agents, tonicity agents mucomimetic agents, and the like. Particularly examples of unstable excipients include but are not limited to cellulose derivatives, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hyaluronic acid, methylcellulose, Dextran, gelatin, polyols, glycerin, polyethylene glycol, polysorbate, propylene glyxol, polyvinyl alcohol, povidone lanolin, mineral oil, paraffin, petrolatum, white ointment, white petrolatum, white, wax, and yellow wax. The terms “stabilizing agent,” and “effective amount” have their aforementioned meanings and preferred ranges.

Yet still further the invention includes an ophthalmic composition comprising an oxidatively unstable excipient and an effective amount of a stabilizing agent. The terms “oxidatively unstable excipient,” “stabilizing agent,” and “effective amount” have their aforementioned meanings and preferred ranges.

Even further still the invention includes a method of stabilizing an ophthalmic composition comprising an oxidatively unstable pharmaceutical ingredient wherein said method comprises

-   -   (a) functionalizing said stabilizing agent with a polymerizable         group,     -   (b) polymerizing an effective amount of the product of step (a)         with at least one type of polymerizable monomer, and     -   (c) contacting the ophthalmic composition comprising an         oxidatively unstable pharmaceutical ingredient with the polymer         of step (b).         The terms oxidatively unstable pharmaceutical ingredient,         effective amount, and stabilizing agents all have their         aforementioned meanings and preferred ranges. The term         functionalizing means chemically bonding a polymerizable group         to said stabilizing agent. Examples of a polymerizable group         includes but are not limited to methacrylate, acrylate,         acrylamide, and styrene. The term polymerizable monomer includes         compounds containing olefinic moieties capable of adding to         radical species, such as propylene, ethylene and the like. The         polymerization product of step (b) may be soluble or insoluble         in the ophthalmic composition. It is preferred that the         polymerization product of step (b) is not soluble in the         ophthalmic composition and as such the polymerization product of         step (b) may be in any form such as rods, discs, containers,         films and the like.

Even further still the invention includes a method of stabilizing an ophthalmic composition comprising an oxidatively unstable excipient wherein said method comprises

-   -   (a) functionalizing said stabilizing agent with a polymerizable         group,     -   (b) polymerizing an effective amount of the product of step (a)         with at least one type of polymerizable monomer, and     -   (c) contacting the ophthalmic composition comprising an         oxidatively unstable excipient with the polymer of step (b).         The terms oxidatively unstable excipient, effective amount,         stabilizing agents, polymerizable group, and polymerizable         monomers all have their aforementioned meanings and preferred         ranges.

Further still the invention includes a container for an ophthalmic composition comprising an oxidatively unstable pharmaceutical ingredient wherein said container comprises the polymerization product of an effective amount of a stabilizing agent functionalized with a polymerizable group and at least one type of polymerizable monomer. The terms oxidatively unstable pharmaceutical ingredient, effective amount, stabilizing agents, polymerizable group, and polymerizable monomers all have their aforementioned meanings and preferred ranges.

Yet, further still the invention includes a container for an ophthalmic composition comprising an oxidatively unstable excipient wherein said container comprises the polymerization product of an effective amount of a stabilizing agent functionalized with a polymerizable group and at least one type of polymerizable monomer. The terms oxidatively unstable excipient, effective amount, stabilizing agents, polymerizable group, and polymerizable monomers all have their aforementioned meanings and preferred ranges.

The advantages of the compositions and methods of this invention are numerous. First ketotifen is known as a oxidatively unstable pharmaceutical ingredient. Compositions containing ketotifen fumarate are known. These compositions contain EDTA and the pH of those compositions is about 5.5. These EDTA solutions stabilize the ketotifen fumarate against oxidative degradation, the pH of these solutions is below the threshold for ocular awareness and it is likely that some patient who use this solution will be uncomfortable due to low pH value of the solution. See Tang, I., Wong, D. M., Yee, D. J. and Harris, M. G. 1996 The pH of multi-purpose soft contact lens solutions. Optom. Vis. Sci. 73:746-749. Adler, F. H. 1959 Physiology of the Eye. Third edition. p. 40. Brawner, L. W. and Jessop, D. G. 1962. A review of contact lens solutions. Contacto 6:49-51. It has been discovered that the stabilizing agents of the invention will reduce the degradation of ketotifen fumarate at higher pH values that those of ketotifen fumarate solutions containing EDTA. The pH of ophthalmic compositions of the invention is preferably between about pH 6.6 and about pH 7.2, more preferably between about pH 6.8 and about pH 7.0.

Second it has been shown that the shelf life of ketotifen fumarate solutions containing DTPA are superior to the shelf life of ketotifen fumarate solutions containing either EDTA or PAA. Third, it is known that the application of heat increases the rate of degradation of many pharmaceutical ingredients. It has been shown that the stabilizing agents of this invention are useful in reducing degradation associated with higher temperature, such as sterilization temperatures.

In order to illustrate the invention the following examples are included. These examples do not limit the invention. They are meant only to suggest a method of practicing the invention. Those knowledgeable in contact lenses as well as other specialties may find other methods of practicing the invention. However, those methods are deemed to be within the scope of this invention.

EXAMPLES

The following abbreviations are used below

PAA

-   -   Polyacrylic Acid, sodium salt having an average molecular weight         of 200,000

EDTA

-   -   Ethylenediamine tetraacetic acid.

Solution A

-   -   Deionized water containing the following ingredients by weight:         NaCl (0.83%), Boric Acid (0.91%), Sodium tetraborate decahydrate         (0.1%)

Initial Testing to Determine Suitability of Ingredients

-   -   It is known that excessive quantities of certain transition         metals and their salts will degrade ketotifen fumarate. The         amount of metals and salts contained within commercially         available ingredients varies, so test batches of Solution A were         evaluated as follows. 200 g Solution A was mixed at ambient         temperature and ketotifen fumarate (5 mg±2 mg) was added and         mixed until homogenous. Six glass vials were filled with 3 mL of         this solution. The vials were stopped with poly         tetrafluoroethylene (“PTFE”) and three of the vials were heated         for eighteen minutes at 124° C. Samples of each treated vial         (1.0-1.5 mL) were analyzed by HPLC and compared to the untreated         controls. If the amount of ketotifen in the treated vials         reduced by less than or equal to five percent (<5%) the         ingredients were determined to be suitable for further studies         and larger batches of Solution A were prepared from these         ingredients.

Example 1 Preparation of Ketotifen Fumarate Solutions with PAA, EDTA

PAA (2000 μg/mL) was added to Solution A, and 50 μg/mL of ketotifen fumarate (approximately 36 μg/mL of ketotifen) was dissolved in the system. EDTA (100 μg/mL) was added to another batch of Solution A, and 50 μg/mL of ketotifen fumarate was dissolved in the system. Negative One and negative twelve (−1.0 and 12.0) diopter etafilcon A contact lenses were added to vials containing 3 mL of each of the above solutions. The vials were sealed with PTFE coated rubber stoppers, sterilized at 124° C. for 18 minutes, and stored at ambient temperature for one year. Samples were harvested throughout the year and analyzed for the presence of ketotifen by HPLC. The results are presented in FIGS. 1 and 2. These results show that there is substantial degradation of the ketotifen over time with PAA and with EDTA.

Example 2 Preparation of Ketotifen Fumarate Solutions with PAA, DTPA

To separate batches of Solution A, Ca₂DTPA (100 μg/mL and 300 μg/mL, 213 and 640 μmoles/L respectively) and 2000 μg/mL (0.2%, approximately 18.51 mmole/L methacrylate content) of PAA were added, and approximately 25 μg/mL of ketotifen fumarate (approximately 18 μg/mL of ketotifen) was dissolved in each of the systems. Three mL samples of each solution were added to individual vials containing contact lenses. Each set of vials was closed with PTFE stoppers, sterilized at 124° C. for 18 minutes, and stored at 80° C. for a period of two weeks. Samples were harvested at various intervals and analyzed for the presence of ketotifen by HPLC. The results are presented in FIG. 3. These results show that there is substantial degradation of the ketotifen over time with PAA but not with the calcium salt of DTPA

Example 3 Ketotifen Fumarate Solutions with Oxidation Catalysts

Ketotifen fumarate (50 μg/mL, approximately 36 μg/mL of ketotifen) was dissolved in Solution A containing approximately 500 μg/mL of either DTPA (approximately 1272 μmoles/L of DTPA) or the sodium salt of EDTA (Na₂C₁₀H₁₄O₈N₂.2H₂O, 1344 μmoles/L of EDTA). Approximately 50 μg/mL of the salts listed in Table 1 were dissolved in each of the solutions and about 3 mL of each solution was dosed into several vials The vials were sealed with PTFE coated rubber stoppers and were subjected to zero, one, two or three sterilization cycles as indicated in Table 1. One sterilization cycle is eighteen 25 minutes of heating at 124° C. Samples were analyzed by HPLC for the concentration of ketotifen at the intervals indicated in Table 2. This data shows that in the presence of oxidative catalysts, DTPA reduces the amount of oxidative degradation as compared to EDTA.

TABLE 1 [salt] (ug/mL) Metal salt Solution 16 MnSO₄•H₂O Manganese 18 KMnO₄ solutions 16 MnOAc₃ 25 FeSO₄•7H₂O Iron 25 Fe₂O₁₂S₃•nH₂O solutions 25 NiSO₄•7H₂O Nickel 25 NiF₆K₂ solutions 25 CuSO₄ Copper 26 Cu₂O solutions

TABLE 2 DTPA stabilized systems EDTA stabilized systems # cycles Fe Cu Ni Mn Fe Cu Ni Mn 0 36.29 36.35 36.40 35.57 36.15 35.78 36.34 33.54 1 35.14 36.13 36.48 34.33 19.41 35.33 34.46 23.98 2 34.10 36.19 36.10 33.71 12.84 34.89 32.75 18.01 3 33.28 35.92 36.22 33.34 7.73 34.71 29.91 12.89 

What is claimed is:
 1. A method to inhibit metal catalyzed oxidative degradation associated with high temperature sterilization of an ophthalmic composition comprising an oxidatively unstable pharmaceutical ingredient wherein said method comprises adding an effective amount of a stabilizing agent to the ophthalmic composition, wherein the stabilizing agent is selected from the group consisting of diethylenetriamineentaacetic acid and salts of diethylenetriamineentaacetic acid, and wherein said ophthalmic composition is a liquid, wherein said oxidatively unstable pharmaceutical ingredient is selected from the group consisting of antiallergenic agents and mast cell stabilizers, and wherein said ophthalmic composition physically contacts a contact lens.
 2. (canceled)
 3. (canceled)
 4. The method of claim 1 wherein the effective amount of the stabilizing agent is about 2.5 μmoles/liter to about 5000 μmoles/liter.
 5. The method of claim 1 wherein the effective amount of the stabilizing agent is about 20 μmoles/liter to about 1000 μmoles/liter.
 6. The method of claim 1 wherein the effective amount of the stabilizing agent is about 100 μmoles/liter to about 600 μmoles/liter.
 7. The method of claim 1 wherein the stabilizing agent is diethylenetriaminepentaacetic acid.
 8. The method of claim 1 wherein the stabilizing agent is diethylenetriaminepentaacetic acid or salts there of and the effective amount of said stabilizing agent is about 100 μmoles/liter to about 1000 μmoles/liter
 9. The method of claim 1 wherein the oxidatively unstable pharmaceutical ingredient is selected from the group consisting of acrivastine, antazoline, astemizole, azatadine, azelastine, buclizine, cetirizine, clemastine, cyclizine, cyproheptadine, ebastine, emedastine, fexofenadine, hydroxyzine, ketotifen, levocabastine, levoceterizine, meclizine, mequitazine, methdilazine, methapyrilene, norastemizole, norebastine, oxymetazoline, pheniramine, picumast, promethazine, terfenadine, triprolidine, pharmaceutically acceptable salts and mixtures thereof.
 10. The method of claim 1 wherein the oxidatively unstable pharmaceutical ingredient is selected from the group consisting of acrivatine, antazoline, astemizole, azatadine, azelastine, clemastine, cyproheptadine, ebastine, emedastine, fexofenadine, hydroxyzine, ketotifen, levocabastine, levoceterizine, meclizine, mequitazine, methdialazine, methapyrilene, norastemizole, norebastine, oxymetazoline, picumast, promethazine, terfenadine, timolol, triprolidine, and pharmaceutically acceptable salts thereof.
 11. The method of claim 1 wherein the oxidatively unstable pharmaceutical ingredient is selected from the group consisting of phenarimine, ketotifen, ketotifen fumarate, nor ketotifen fumarate olopatadine and mixtures thereof.
 12. (canceled) 13-67. (canceled) 